Compare INTT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTT | MCRB |
|---|---|---|
| Founded | 1981 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.9M | 162.7M |
| IPO Year | 1997 | 2015 |
| Metric | INTT | MCRB |
|---|---|---|
| Price | $7.59 | $17.21 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | $12.00 | ★ $14.33 |
| AVG Volume (30 Days) | 34.3K | ★ 323.1K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.62 |
| Revenue | ★ $117,606,000.00 | $351,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.60 | N/A |
| P/E Ratio | ★ N/A | $27.79 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.24 | $6.53 |
| 52 Week High | $9.77 | $29.98 |
| Indicator | INTT | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 47.60 |
| Support Level | $7.53 | $16.50 |
| Resistance Level | $8.00 | $17.52 |
| Average True Range (ATR) | 0.47 | 1.14 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 23.96 | 26.56 |
inTest Corp is a supplier of test and process solutions for use in manufacturing and testing across a range of markets including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications. The company manages its business as three operating segments which is also their reporting units that includes Electronic Test, Environmental Technologies and Process Technologies. Electronic Test (which includes semiconductor test equipment, flying probe and in-circuit testers), Environmental Technologies (which includes its thermal test, process and storage products) and Process Technologies (which includes induction heating and video imaging products). The company operates their business and sells its products both domestically and internationally.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.